Shares of Cipla Ltd came under selling pressure on Friday, extending a phase of relative underperformance against the broader market. The decline follows fresh brokerage commentary highlighting vulnerabilities in Cipla’s US business at a time when investors were already reassessing the sustainability of its recent earnings momentum.

Cipla stock fell 3.48 percent in early trade to around ₹1,385, taking its one-year performance to a decline of roughly 4 percent. This contrasts with a double-digit gain in the Nifty 50 over the same period, underscoring growing concerns around company-specific execution risks rather than sector-wide weakness.

At the heart of the issue is Lanreotide, a key complex generic product in Cipla’s US portfolio and one of its top three revenue contributors in that market.

Cipla has disclosed that manufacturing of Lanreotide has been temporarily paused at its European contract manufacturing partner to support remediation efforts following a US Food and Drug Administration inspection. The inspection at Pharmathen’s Rodopi facility in Greece reportedly resulted in nine observations, prompting corrective actions and a production halt.

Lanreotide contributes an estimated $150 million in annual revenue for Cipla, with the company holding about a 22 percent market share in the US. Management has indicated that resupply is expected to resume in the first half of FY27, but the gap until then introduces uncertainty around volumes, market share retention, and near-term earnings visibility.

Brokerages have responded by reassessing forward estimates, particularly for FY26 and FY27.

The Lanreotide disruption comes at a sensitive juncture for Cipla’s US business. Another major profit contributor, gRevlimid, is already in the process of phasing out due to loss of exclusivity. Together, these factors reduce earnings buffers just as competition in other inhalation and respiratory generics is intensifying.

From an investor perspective, the concern is not only the temporary loss of revenue but also the risk that prolonged supply disruption could allow competitors to entrench themselves, making it harder for Cipla to regain share even after manufacturing resumes.

This risk dynamic explains the sharp market reaction despite management clarity on the expected resumption timeline.

Morgan Stanley maintained its Underweight stance on Cipla and cut its target price to ₹1,292. The brokerage flagged the combined impact of the gRevlimid phase-out and Lanreotide supply issues, particularly in Q4 FY26. It reduced earnings estimates by 2 percent for FY26 and 1 percent for FY27, warning that extended disruption could create downside risks for FY27 and FY28.

Nuvama also turned more cautious, downgrading the stock to Reduce with a lower target price of ₹1,360. Nuvama highlighted three pressure points: uncertainty around Lanreotide resupply, expiry-related impact from gRevlimid, and rising competition in Cipla’s proposed generic Advair following approval for a rival product by Lannett.

The brokerage noted that manufacturing at Pharmathen is expected to restart only in the first half of FY27, keeping near-term earnings visibility weak.

Not all views are negative. Nomura believes much of the Lanreotide risk is already reflected in the stock price, noting that Cipla shares have fallen about 6.5 percent since the issue first surfaced earlier this month. Nomura has maintained a Buy rating with a target price of ₹1,770, suggesting limited downside from current levels if disruptions remain temporary.

In the near term, Cipla’s valuation is likely to remain capped by uncertainty around its US revenue trajectory. Even if Lanreotide supplies resume as guided, FY26 earnings may still see a visible dent due to lost sales and higher remediation-related costs.

For the Indian pharmaceutical sector, the episode reinforces a familiar risk: dependence on a few high-value complex generics manufactured through global supply chains increases vulnerability to regulatory actions abroad. While not systemic, such events often trigger short-term de-rating until clarity improves.

The primary risk remains execution at the contract manufacturing partner and the pace of regulatory remediation. Any adverse follow-up from the USFDA, delays beyond H1 FY27, or aggressive competitive pricing during Cipla’s absence from the market could materially alter earnings outcomes.